Close Menu

NEW YORK – Singapore-based molecular diagnostic company MiRxes announced Monday it has received CE marking and Provisional Authorization from the Singapore Health Sciences Authority for its multiplex SARS-CoV-2 and influenza A/B test. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.